This study looks at a new treatment, AGN-193408 SR, for people with **open-angle glaucoma** (OAG) or **ocular hypertension** (OHT). Glaucoma is a condition where pressure in the eye can lead to vision loss, and ocular hypertension is when the pressure is higher than normal but hasn't yet damaged the eye. The study is in multiple stages: starting with different doses to see which works best (Cohort 1), and then comparing effects in separate groups (Cohorts 2 and 3).

• This study may require you to stop current eye pressure treatments.
• Participants must have had cataract surgery at least 4 months prior.
• Avoid if you have allergies to study medications or recent eye surgeries.

Participants must be okay with **stopping their current eye pressure treatments** during the study. They should not have had certain eye surgeries recently, like laser procedures or cataract surgeries. People with allergies to the study drugs or those needing new eye surgeries soon should not join. This study involves close monitoring to ensure safety and effectiveness of the new treatment.